-
Something wrong with this record ?
Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases
K. Mellgren, A. Attarbaschi, O. Abla, S. Alexander, S. Bomken, E. Bubanska, A. Chiang, M. Csóka, A. Fedorova, E. Kabickova, L. Kapuscinska-Kemblowska, R. Kobayashi, Z. Krenova, F. Meyer-Wentrup, N. Miakova, M. Pillon, G. Plat, A. Uyttebroeck, D....
Language English Country Germany
Document type Journal Article, Multicenter Study
NLK
ProQuest Central
from 1997-03-01
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-03-01
Health & Medicine (ProQuest)
from 1997-03-01
Springer Nature OA/Free Journals
from 1955-03-01
- MeSH
- Child MeSH
- Outcome Assessment, Health Care methods MeSH
- Remission Induction MeSH
- Infant MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- International Cooperation MeSH
- Adolescent MeSH
- Young Adult MeSH
- Lymphoma, T-Cell, Peripheral therapy MeSH
- Child, Preschool MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Retrospective Studies MeSH
- Hematopoietic Stem Cell Transplantation methods statistics & numerical data MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.
Belarusian Research Center for Pediatric Oncology Hematology and Immunology Minsk Belarus
Clinic of Paediatrics Haemathology and Oncology Medical University of Gdansk Gdansk Poland
Department of Pediatric Oncology Hôpital des Enfants Toulouse France
Department of Pediatrics Sapporo Hokuyu Hospital Sapporo Japan
Pediatric Hematology and Oncology Semmelweis University Budapest Hungary
Pediatric Hematology and Oncology University Hospitals Leuven Leuven Belgium
Pediatric Hematology and Oncology University of Padova Padova Italy
Pediatric Oncology and Hematology University Hospital Brno Czech Republic
Princess Maxima Center for Pediatric Oncology Utrecht The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013797
- 003
- CZ-PrNML
- 005
- 20170425122500.0
- 007
- ta
- 008
- 170413s2016 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00277-016-2722-y $2 doi
- 035 __
- $a (PubMed)27270301
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Mellgren, K $u Department of Pediatric Hematology and Oncology, The Queen Silvia's Hospital for Children, Rondvägen 10, 41685, Göteborg, Sweden. karin.mellgren@vgregion.se.
- 245 10
- $a Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases / $c K. Mellgren, A. Attarbaschi, O. Abla, S. Alexander, S. Bomken, E. Bubanska, A. Chiang, M. Csóka, A. Fedorova, E. Kabickova, L. Kapuscinska-Kemblowska, R. Kobayashi, Z. Krenova, F. Meyer-Wentrup, N. Miakova, M. Pillon, G. Plat, A. Uyttebroeck, D. Williams, G. Wróbel, U. Kontny, . ,
- 520 9_
- $a Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $x statistika a číselné údaje $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mezinárodní spolupráce $7 D007391
- 650 _2
- $a periferní T-buněčný lymfom $x terapie $7 D016411
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a hodnocení výsledků zdravotní péče $x metody $7 D017063
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Attarbaschi, A $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria. $7 gn_A_00009850
- 700 1_
- $a Abla, O $u Department of Pediatrics, Division of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. $7 gn_A_00000620
- 700 1_
- $a Alexander, S $u Department of Pediatrics, Division of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada. $7 gn_A_00003921
- 700 1_
- $a Bomken, S $u Department of Paediatric Haematology and Oncology, Great North Children's Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- 700 1_
- $a Bubanska, E $u Department of Pediatric Oncology and Hematology, University Children's Hospital, Banska Bystrica, Slovakia.
- 700 1_
- $a Chiang, A $u Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
- 700 1_
- $a Csóka, M $u Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Fedorova, A $u Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
- 700 1_
- $a Kabickova, E $u Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Kapuscinska-Kemblowska, L $u Clinic of Paediatrics Haemathology and Oncology, Medical University of Gdansk, Gdansk, Poland.
- 700 1_
- $a Kobayashi, R $u Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
- 700 1_
- $a Krenova, Z $u Pediatric Oncology and Hematology, University Hospital, Brno, Czech Republic.
- 700 1_
- $a Meyer-Wentrup, F $u Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a Miakova, N $u Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
- 700 1_
- $a Pillon, M $u Pediatric Hematology and Oncology, University of Padova, Padova, Italy.
- 700 1_
- $a Plat, G $u Department of Pediatric Oncology, Hôpital des Enfants, Toulouse, France.
- 700 1_
- $a Uyttebroeck, A $u Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Williams, D $u Pediatric Hematology and Oncology, Addbrooke's Hospital, Cambridge University Hospitals Foundation Trust, Cambridge, UK.
- 700 1_
- $a Wróbel, G $u Bone Marrow Transplantation and Pediatric Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.
- 700 1_
- $a Kontny, U $u Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Aachen, Germany.
- 700 1_
- $a ,
- 773 0_
- $w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 95, č. 8 (2016), s. 1295-305
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27270301 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170425122817 $b ABA008
- 999 __
- $a ok $b bmc $g 1200262 $s 974575
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 95 $c 8 $d 1295-305 $e 20160607 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
- LZP __
- $a Pubmed-20170413
